Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, PR China.
Department of Cardiology, Affiliated Hospital of Guilin Medical University, Guilin, PR China.
Am J Pathol. 2020 May;190(5):1095-1107. doi: 10.1016/j.ajpath.2019.11.010. Epub 2020 Jan 16.
Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer worldwide, and it is the primary histologic subtype of liver cancer, with high incidence and poor prognosis. Recently, numerous long noncoding RNAs have been reported to be associated with the tumorigenesis of HCC; however, the underlying mechanisms of long intergenic nonprotein coding RNA 0152 (LINC00152) action in HCC are poorly understood. Herein, we identified a significant up-regulation of LINC00152 in both HCC tissues and cell lines. Functional studies showed that knockdown of LINC00152 inhibited cell proliferation, migration, and invasion, but promoted cell apoptosis, indicating its oncogenic functions in HCC tumorigenesis. Mechanistically, LINC00152 functioned as an efficient miR-139 sponge, thereby releasing the suppression of PIK3CA (a target gene of miR-139). Anti-miR-139 rescued the inhibition of cell proliferation, migration, and invasion induced by LINC00152 knockdown. Similarly, PIK3CA-overexpressing plasmid also reversed miR-139-mediated biological functions in HCC cells. Taken together, our study revealed a crucial regulatory network of LINC00152/miR-139/PIK3CA axis in the tumorigenesis of HCC, implying that LINC00152 may be a biomarker and novel therapeutic target for further clinical therapy of HCC.
肝细胞癌(HCC)是全球第五大常见癌症,是肝癌的主要组织学亚型,发病率高,预后差。最近,大量长非编码 RNA 被报道与 HCC 的发生有关;然而,长基因间非蛋白编码 RNA 0152(LINC00152)在 HCC 中的作用的潜在机制仍知之甚少。在此,我们发现 LINC00152 在 HCC 组织和细胞系中均显著上调。功能研究表明,LINC00152 的敲低抑制了细胞增殖、迁移和侵袭,但促进了细胞凋亡,表明其在 HCC 肿瘤发生中具有致癌功能。机制上,LINC00152 作为有效的 miR-139 海绵,从而释放了对 PIK3CA(miR-139 的靶基因)的抑制。抗 miR-139 挽救了 LINC00152 敲低诱导的细胞增殖、迁移和侵袭的抑制。同样,PIK3CA 过表达质粒也逆转了 miR-139 在 HCC 细胞中的生物学功能。总之,我们的研究揭示了 LINC00152/miR-139/PIK3CA 轴在 HCC 发生中的关键调控网络,表明 LINC00152 可能是 HCC 进一步临床治疗的生物标志物和新的治疗靶点。